Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph Crott

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Vaccine|October 9, 2007
Economic analysis of HPV-vaccines: not so simple?Ralph Crott
Bulletin Du Cancer|January 7, 2004
[Assessment of cancer cost at the international level : challenges and methodological approaches]Ralph Crott
Expert Opinion on Pharmacotherapy|August 19, 2007
The economics of temozolomide in brain cancerRalph Crott
Pharmacoeconomics|June 24, 2004
Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a reviewRalph Crott
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2014
Mapping algorithms from QLQ-C30 to EQ-5D utilities: no firm ground to stand on yetRalph Crott
Pharmacoeconomics - Open|April 7, 2018
Direct Mapping of the QLQ-C30 to EQ-5D Preferences: A Comparison of Regression MethodsRalph Crott
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|May 18, 2010
Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferencesRalph Crott, Andrew Briggs
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 19, 2005
Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trialsNiels Neymark, Ralph Crott
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Cost-effectiveness of antiemetics use during cancer chemotherapyJean Lachaine, Ralph Crott
Advances in Experimental Medicine and Biology|August 12, 2003
EORTC research and development: achievements and future perspectivesDenis Lacombe, Ralph Crott, Françoise Meunier
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Vaccine|October 9, 2007
Economic analysis of HPV-vaccines: not so simple?Ralph Crott
Bulletin Du Cancer|January 7, 2004
[Assessment of cancer cost at the international level : challenges and methodological approaches]Ralph Crott
Expert Opinion on Pharmacotherapy|August 19, 2007
The economics of temozolomide in brain cancerRalph Crott
Pharmacoeconomics|June 24, 2004
Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a reviewRalph Crott
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2014
Mapping algorithms from QLQ-C30 to EQ-5D utilities: no firm ground to stand on yetRalph Crott
Pharmacoeconomics - Open|April 7, 2018
Direct Mapping of the QLQ-C30 to EQ-5D Preferences: A Comparison of Regression MethodsRalph Crott
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|May 18, 2010
Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferencesRalph Crott, Andrew Briggs
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 19, 2005
Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trialsNiels Neymark, Ralph Crott
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Cost-effectiveness of antiemetics use during cancer chemotherapyJean Lachaine, Ralph Crott
Advances in Experimental Medicine and Biology|August 12, 2003
EORTC research and development: achievements and future perspectivesDenis Lacombe, Ralph Crott, Françoise Meunier
Pageof 5